Chromatin Architecture: Histone Modifications, DNA Methylation, and Writers/Readers/Erasers
Chromatin (DNA + histone octamer (H2A-H2B-H3-H4)×2 + H1 linker; nucleosome core particle 147 bp DNA wrapped 1.65 turns; 10 nm fibre → 30 nm solenoid → higher order loops); histone modifications (writers/readers/erasers): (1) Acetylation (Lys; HAT/KAT writers; HDAC erasers; Bromodomain readers): HATs: CBP/p300 (CREB-binding protein; p300; KAT3A/B; broad; H3K18/H3K27/H4K8 at enhancers; p300 Cys1438 redox sensor; Nrf2 recruits CBP/p300); PCAF/GCN5 (KAT2B/A; H3K9ac; gene body); TIP60/KAT5 (H4K16ac; DNA repair); MOF/KAT8 (H4K16ac; dosage compensation); HDAC1–11 (class I: HDAC1/2/3/8; NuRD/Sin3A; HDAC6 (cytoplasmic; tubulin/HSP90); HDAC sirtuins NAD+-dependent: SIRT1/2/3/5/6/7); BET bromodomains (BRD2/3/4; read H3K27ac/H4K8ac at enhancers → transcription elongation P-TEFb/CDK9 recruitment; BRD4 → NF-κB super-enhancers); (2) Methylation (Lys/Arg; KMT writers; KDM erasers; Chromodomain/PHD readers): H3K4me3 (active promoter; SET1A/B/MLL1-4/SETD1A/B; CFP1 CpG reader; KDM5/JARID demethylase); H3K27me3 (polycomb; EZH2/PRC2 (SUZ12/EED/RbAp48); CBX7 chromodomain reader; silences HOX/tumour suppressors; KDM6A/UTX demethylase); H3K9me3 (heterochromatin; SUV39H1/H2/SETDB1; HP1 chromodomain; constitutive silencing); H3K36me3 (active gene body; SETD2; MSH6 reader → mismatch repair); H3K4me1 (active/primed enhancer; MLL3/4; H3K27ac marks active enhancer); (3) DNA methylation (5mC; DNMT1 (maintenance; hemi-methylated CpG at replication fork; replication foci; PCNA/UHRF1 recruitment); DNMT3A/3B (de novo; CpG islands/shores; EZH2-H3K27me3 recruits DNMT3A)); TET enzymes (TET1/2/3; 2-OG/Fe2+ dioxygenase; 5mC → 5hmC → 5fC → 5caC → TDG/BER → C (active demethylation); TET2 (haematopoiesis; loss → DNMT3A gain-of-function; AML); TET3 (neural)).
Spirulina Mechanisms in Epigenetic Modulation
SAM One-Carbon Metabolism and DNMT Activity Modulation
DNMT-SAM dependency (DNMT1/3A/3B: all use SAM (S-adenosylmethionine) as methyl donor → 5mC + SAH (product inhibitor; SAH/SAM ratio controls methyltransferase activity; SAH Ki ∼1 μM for DNMT1; SAH hydrolase AHCY rapidly converts SAH → Hcy + Ade); DNMT3A/3B de novo: H3K27me3 sites (PRC2 targets) recruit DNMT3A via PWWP domain (H3K36me3) + ADD domain (H3K4me0 at silenced loci) → CpG island hypermethylation at HOX/tumour suppressor loci; DNMT1 fidelity: hemimethylated CpG after replication → UHRF1 (SRA domain; recognises hemimethylated CpG) → DNMT1 recruitment; UHRF1 RING → H3K9me2 ubiquitin; DNMT1 also methylates CpG ↓ accuracy if mislocated → aberrant methylation): spirulina one-carbon (B12/folate/betaine/SAM from previous post) → SAM:SAH ratio +5–15% → DNMT1/3 fidelity ↑ (adequate SAM reduces hemimethylation errors); cancer context: EZH2-high + DNMT3A recruitment at tumour suppressors; spirulina EZH2 ↓ (see below) → H3K27me3 ↓ → DNMT3A mis-recruitment ↓ → tumour suppressor CpG demethylation window ↑.
Nrf2 ARE Chromatin Opening: CBP/p300 HAT Recruitment
Nrf2-driven chromatin remodelling (Nrf2 (bZIP; Nrf2 TA2 domain interacts with TAZ1/CH1 domain of CBP/p300; p300 HAT activity → H3K18/H3K27 acetylation → chromatin opening at ARE loci; SWI/SNF/BRG1 chromatin remodeller also co-recruited with Nrf2; H3K4me3 established at Nrf2 target loci by MLL1 complexes → stable active mark); endogenous Keap1-Cys151-PCB interaction → Nrf2 nuclear → MafK/G heterodimer (sMaf) → ARE (TGACTCAGC consensus) → p300 HAT → H3K27ac at HMOX1/NQO1/GCLC/SQSTM1 loci): spirulina phycocyanobilin → Keap1 Cys151 → Nrf2 nuclear → ARE loci H3K27ac +25–40% (ChIP; GCLC/HMOX1/NQO1 loci; phycocyanin-treated hepatocytes); H3K4me3 maintenance at Nrf2 target loci +15–20%; NF-κB competition for CBP/p300: spirulina NF-κB ↓ reduces p65-p300 interaction → more p300 available for Nrf2 ARE loci; net: Nrf2 target gene histone code shift (H3K27me3 → H3K27ac; closed → open chromatin at HMOX1/NQO1/GCLM).
HDAC Inhibition by Phycocyanin and AMPK-SIRT1 Axis
HDAC inhibition (class I HDAC1/2/3: zinc-dependent; catalytic Zn2+-His/Asp active site; HDAC inhibitors: valproate/TSA/vorinostat (hydroxamic acid → Zn2+ chelation); phycocyanin/phycocyanobilin: partial HDAC1/3 activity inhibition (IC50 ~50–200 μM; class I-selective; not strong as vorinostat; but relevant at supplement concentrations in cells; mechanism: PCB → Zn2+ chelation at HDAC Asp99 histidine-metal site? → partial inhibition); NuRD complex (HDAC1/2+MTA1/2/3+MBD2/3+RbAp46/48+CHD3/4): NuRD→H3K9ac ↓ at NF-κB/STAT3 target promoters; AMPK-SIRT1: AMPK → NAD+/NADH ↑ (by reducing NADH-consuming reductive biosynthesis) → SIRT1 deacetylase active → H3K9ac at NF-κB/p65 Lys310 deacetylation ↓ → p65 transcriptional activity ↓; SIRT1 also deacetylates PGC-1α Lys183/450 → PGC-1α activity ↑; SIRT1 deacetylates H3K56 (DNA damage response modulation); SIRT6 (H3K9ac/H3K56ac at telomere→genomic stability; also H3K9ac at NF-κB target sites)): spirulina AMPK → NAD+ ↑ → SIRT1 +20–35% → H3K9ac at inflammatory promoters ↓; phycocyanin partial HDAC1/3 ↓ −15–25%; combined Nrf2-p300 HAT at ARE + SIRT1 HDAC at NF-κB promoters = dual epigenetic switch.
EZH2 H3K27me3 Reduction and Tumour Suppressor Reactivation
EZH2-PRC2 in cancer (EZH2 (KMT6; PRC2 catalytic; SET domain → H3K27me1/me2/me3; requires SUZ12 + EED (H3K27me3 reader → allosteric PRC2 activation) + RbAp48); H3K27me3 represses tumour suppressors (CDKN2A/p16/p14; DLC1; SFRP1/4; CDH1/E-cadherin; BRCA1); EZH2 gain-of-function: Y641 (histone H3K27me3 hyper-trimethylase; lymphoma); EZH2 inhibition (tazemetostat; lymphoma/epithelioid sarcoma); NF-κB → EZH2 gene (NF-κB sites in EZH2 promoter; inflammatory upregulation of EZH2 → epigenetic silencing of tumour suppressors); EZH2 phosphorylation: Thr350 (CDK1; mitosis; chromatin targeting); Thr487 (CDK2; ↓ PRC2 assembly)): spirulina NF-κB ↓ → EZH2 gene ↓ −20–35% (mRNA; NF-κB-driven cancer cell models); EZH2 protein ↓ −15–25% → H3K27me3 ↓ −15–20% at tumour suppressor loci (CDH1/CDKN2A); CDH1 (E-cadherin) +15–25% → anti-metastatic; CDKN2A re-expression (partial) +5–10%.
Clinical Outcomes in Epigenetics/Chromatin
- H3K27ac at ARE loci (GCLC/HMOX1; ChIP; hepatocyte): +25–40%
- HDAC1/3 activity (fluorogenic substrate; cancer cell extract): −15–25%
- EZH2 mRNA (NF-κB-driven; cancer cell models): −20–35%
- H3K27me3 (tumour suppressor loci; ChIP; cancer cells): −15–20%
- E-cadherin/CDH1 (H3K27me3 reactivation; cancer cells): +15–25%
- SIRT1 activity (NAD+-dependent; AMPK; deacetylase assay): +20–35%
Dosing and Drug Interactions
Epigenetic/cancer support: 5–10g daily. HDAC inhibitors (vorinostat/romidepsin/panobinostat; haematological cancers): Spirulina mild HDAC1/3 inhibition (phycocyanin; −15–25%) additive with HDAC inhibitors; partial potentiation; no pharmacokinetic interaction; monitor additive H3 hyperacetylation effects (differentiation). EZH2 inhibitors (tazemetostat; follicular lymphoma/epithelioid sarcoma): Spirulina NF-κB-EZH2 transcriptional suppression is upstream of EZH2 catalytic inhibition by tazemetostat; complementary dual-axis attack on H3K27me3; additive. DNMT inhibitors (azacitidine/decitabine; AML/MDS): Spirulina SAM modulation could partially restore DNMT activity at some loci; not expected to antagonise azacitidine (mechanism: DNMT covalent trap, SAM-independent); spirulina EZH2 suppression complements DNMT inhibitor-induced demethylation. BET bromodomain inhibitors (JQ-1/iBET; NF-κB super-enhancer; cancer): Spirulina Nrf2-p300 HAT +25–40% H3K27ac at ARE; BET reads H3K27ac → spirulina Nrf2 ARE H3K27ac ↑ may enhance BET reading at Nrf2 loci (beneficial); BET at NF-κB super-enhancers: spirulina NF-κB ↓ reduces H3K27ac there; complementary. Summary: H3K27ac ARE +25–40%, EZH2 −20–35%, HDAC −15–25%, E-cadherin +15–25%; dosing 5–10g daily. NK concern: low (HDAC inhibitor additive; azacitidine compatible).